The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

A groundbreaking study from the University of Oklahoma reveals that the hormone FGF21 can reverse fatty liver disease by ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...

Doctors generally have an easier time diagnosing type 1 diabetes in kids, who present with classic symptoms of excessive thirst, excessive urination, and weight loss. “Children often have a really ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

This Week’s Wellness Wednesday, we’re taking a look at a topic that crosses everyone’s mind, weight loss. There are many ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...